dupilumab
Also known as Dupixent®, REGN668, SAR231893
Dupilumab, sold under the brand name Dupixent, is a monoclonal antibody blocking interleukin 4 and interleukin 13 receptor signalling (IL-4R, IL-13R), used for allergic diseases such as atopic dermatitis (eczema), asthma and nasal polyps which result in chronic sinusitis. It is also used for the treatment of eosinophilic esophagitis, prurigo nodularis and chronic obstructive pulmonary disease.
Key facts
- Drug.type
- mab
- Drug.image
- Dupilumab fab binding to IL-4.png
- Drug.alt
- 3D structure of dupilumab's antigen binding fragment complexed with a human IL-4 receptor sub-unit alpha
- Drug.caption
- Dupilumab antigen binding fragment (orange and green) bound to a human IL-4 receptor alpha (purple)
- Drug.mab_type
- mab
- Drug.source
- u
- Drug.target
- Interleukin 4 (IL4) receptor alpha
- Drug.tradename
- Dupixent
- Drug.MedlinePlus
- a617021
- Drug.DailyMedID
- Dupilumab
- Drug.pregnancy_AU
- B1
- Drug.routes_of_administration
- Subcutaneous
Article
12 sectionsContents
- Medical uses
- History of extension of indications
- Side effects
- Pharmacology
- Mechanism of action
- Pharmacokinetics
- Society and culture
- Legal status
- Cost
- History
- See also
- References
Dupilumab, sold under the brand name Dupixent, is a monoclonal antibody blocking interleukin 4 and interleukin 13 receptor signalling (IL-4R, IL-13R), used for allergic diseases such as atopic dermatitis (eczema), asthma and nasal polyps which result in chronic sinusitis. It is also used for the treatment of eosinophilic esophagitis, prurigo nodularis and chronic obstructive pulmonary disease.
The most common side effects reported by the US Food and Drug Administration (FDA) include injection site reactions, upper respiratory tract infections, joint pain, and herpes viral infections. The most common side effects reported by the European Medicines Agency (EMA) include injection-site reactions (such as redness, swelling including due to fluid build-up, itching and pain), conjunctivitis (redness and discomfort in the eye) including conjunctivitis due to allergy, joint pain, cold sores, and increased blood levels of a type of white blood cell called eosinophils. It was developed by Regeneron Pharmaceuticals and Sanofi Genzyme. It received approval from the US Food and Drug Administration (FDA) for moderate-to-severe atopic dermatitis in 2017, and for asthma in 2018. The FDA considers it to be a first-in-class medication.